Episode Details

Scientists just dropped a game-changer: a new cancer jab called amivantamab wiped out tumors in 15 patients with advanced, treatment-resistant head and neck cancer — some even completely vanished. This triple-action drug works by blocking growth, stopping escape routes, and revving up the immune system. In a trial of over 100 patients, more than a third saw tumors shrink, and survivors lived over 12 months on average. Patients report dramatic improvements — one regained the ability to eat and speak normally. Administered under the skin, it’s far easier than IV treatments, with mostly mild side effects. Experts call the results unprecedented — especially for HPV-negative cancers, which are notoriously hard to treat. This breakthrough shines a light on the power of relentless cancer research and offers hope to those with few options left.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/29483218cf8a4bac